Sort   by:  
 Page size 
ProteomicsCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
The cellular processes that govern tumor resistance to immunotherapy remain poorly understood. To gain insight into these processes, we perform a genome-scale CRISPR activation screen for genes that enable human melanoma cells to evade cytotoxic T cell killing. Overexpression of four top candidate g...
ORGANISM(S): Homo sapiens (Human) 
2022-02-09 | PXD031532 | Pride
Shotgun proteomics B3gnt2 Co-ip Melanoma 
UnknownStructures and mechanism of human glycosyltransferase β1,3-N-acetylglucosaminyltransferase 2 (B3GNT2), an important player in immune homeostasis.
Not available
S-EPMC7948737 | biostudies-literature
UnknownN-Glycosylation of LRP6 by B3GnT2 Promotes Wnt/β-Catenin Signalling.
Not available
S-EPMC10047360 | biostudies-literature
UnknownB3GNT2, GPR35, PSMG1 Gene Polymorphisms Are Related With Susceptibility and Severity of Ankylosing Spondylitis in Chinese Han Population.
Not available
S-EPMC12308515 | biostudies-literature
UnknownCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.
Not available
S-EPMC8956604 | biostudies-literature
GenomicsCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
PRJNA669676 | ENA
GenomicsCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
PRJNA670002 | ENA
GenomicsCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
PRJNA670003 | ENA
GenomicsCRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity (sgRNA distribution)
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity (sgRNA distribution)
PRJNA809721 | ENA
UnknownA genetic association study of circulating coagulation factor VIII and von Willebrand factor levels.
Not available
S-EPMC11443575 | biostudies-literature
Sort   by:  
 Page size